Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from IDEAYA Biosciences ( (IDYA) ) is now available.
On June 26, 2025, IDEAYA Biosciences appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer. This strategic appointment may influence the company’s financial management and operational strategies.
The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Spark’s Take on IDYA Stock
According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.
IDEAYA Biosciences’ stock score is primarily impacted by its financial performance challenges, including declining revenues and net losses. Positive technical indicators provide some support, indicating potential short-term momentum. However, the lack of profitability and valuation concerns weigh heavily on the overall score.
To see Spark’s full report on IDYA stock, click here.
More about IDEAYA Biosciences
Average Trading Volume: 1,439,189
Technical Sentiment Signal: Sell
Current Market Cap: $1.93B
For a thorough assessment of IDYA stock, go to TipRanks’ Stock Analysis page.